zPREDICTA, a provider of tumor-specific 3D cell culture models for the in vitro testing of anti-cancer therapeutics, has entered into a strategic collaboration with LabCorp. The agreement will support the adoption of zPREDICTA’s proprietary 3D cell culture platform for preclinical testing and research studies in the biopharmaceutical industry.   The collaboration combines zPREDICTA’s strengths in the development of clinically relevant 3D cell culture models with LabCorp’s strengths in drug devel...